NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Matchar DB, McCrory DC, Orlando LA, et al. Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating Essential Hypertension [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2007 Nov. (Comparative Effectiveness Reviews, No. 10.)
This publication is provided for historical reference only and the information may be out of date.
Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating Essential Hypertension [Internet].
Show details| Study | Interventions and study design | Patient characteristics | Results | Comments/quality/applicability |
|---|---|---|---|---|
| StudyID | Geographical location:
[city & state(U.S.) or city & country
(foreign)] Study dates: [month & year] Funding source: Interventions: [For each treatment arm, describe drug, dose (incl. titration protocol), and number of patients randomized] Study design: [Delete all but one] RCT, parallel-groupD RCT, crossover Other [specify] Blinding: [For each item, Yes/No/NR = not reported]
Was allocation concealment adequate? [e.g., computer-generated list or central randomization] Yes/No/NR Baseline/run-in period: [length & intervention, or NA = not applicable]D Washout period(s): [crossover trials only; length] Duration of treatment: [post-baseline/run-in; days, weeks, months] Duration of post-treatment followup: [days, weeks, months, or NA = not applicable] | Number of patients:
Age: Mean (SD):D Median: Range: Sex (n [%]): Female: Male: Race/ethnicity (n [%]): Baseline blood pressure: [by treatment group, if given; indicate how assessed] Concurrent medications (n [%]): Comorbidities (n [%]): Recruitment setting: [Inclusion/exclusion criteria: describe these as reported in article. If tolerability was assessed during run-in or used as an incl/excl criterion, please note this.] Inclusion criteria: Exclusion criteria: | [Where necessary, specify how outcomes
were defined and assessed. Report quantitative data and
p-values, where available; give N’s for specific outcomes if
these differ from N’s randomized; give time point(s) for
abstracted data and note other time points available in the
article. Include any results reported separately for subgroups
of patients based on demographic characteristics (age, racial
and ethnic groups, sex), use of other medications concurrently,
or comorbidities.] 1) Blood pressure: [Prefer seated trough BP, if reported; if BP outcomes other than the one(s) you abstract are reported, list these] 2) Rate of use of a single antihypertensive agent for BP control: 3) Mortality: [all-cause, cardiovascular disease-specific, and cerebrovascular disease-specific] 4) Morbidity: [cardiac events (MI), heart failure, cerebral vascular disease or events (incl. stroke), symptomatic coronary artery disease, end-stage renal disease, PVD, quality of life] 5) Safety: [overall adverse events (AEs), withdrawals due to AEs, serious AEs reported, switch rates] 6) Specific adverse events: [including, but not limited to: weight gain, impaired renal function, angioedema, cough]: 7) Persistence/adherence: 8) Lipid levels: 9) Progression to type 2 diabetes: 10) Markers of carbohydrate metabolism/diabetes control: [HbA1c, insulin or other diabetes med dosage, fasting plasma glucose, aggregated measures of serial glucose measurements] 11) LV mass/function: 12) Creatinine/GFR: 13) Proteinuria: | [IF ARTICLE SHOULD BE EXCLUDED, PLEASE
EXPLAIN WHY HERE] General comments: [Comment here on biases, etc., affecting clinical interpretation] Quality assessment: [Assign an overall quality rating of “Good,” “Fair,” or “Poor” based on the definitions provided in the guidance sheet. If study is rated as “Fair” or “Poor,” note important limitations in internal validity (see guidance sheet assessing quality) under “Comments”, below.] Overall rating: Comments: Applicability: [List the most important (up to 3) limitations affecting applicability, if any, based on the list given in the guidance sheet on assessing applicability.] |
- Data Abstraction Form - Comparative Effectiveness of Angiotensin-Converting Enzy...Data Abstraction Form - Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating Essential Hypertension
Your browsing activity is empty.
Activity recording is turned off.
See more...